Loading patent…
AssigneeVigil Neuroscience, Inc.
InventorsMatthew BRENNAN, Judith Dunn, Richard Fisher, Berkley A. Lynch, Steven Robinette
Estimating the term…
The present invention provides a method of treating a disease or disorder caused by and/or associated with CSF1R dysfunction in a human patient, the method comprising administering to the patient in need thereof an effective amount of a compound that increases the activity of triggering receptor expressed on myeloid cells 2 (TREM2). In some embodiments, compound that increases the activity of TREM2 is an agonist of TREM2. In some embodiments, the agonist of TREM2 is a small molecule agonist of TREM2 or an antibody agonist of TREM2.
A method of treating a disease or disorder caused by and/or associated with colony-stimulating factor 1 receptor (CSF1R) dysfunction in a human patient, the method comprising administering to the patient an effective amount of an agonist of triggering receptor expressed on myeloid cells 2 (TREM2).
-12. (canceled)
-26. (canceled)
(canceled)
Dependencies are inferred from the claim text.